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AMPK amplifies Huntington’s disease
J
u et al. describe how 
hyperactivation of AMP-
activated protein kinase 
(AMPK) promotes neurode-
generation in Huntington’s 
disease (HD).
The aggregation of mu-
tant Huntingtin protein in HD 
disrupts many cellular pro-
cesses, including metabolism. 
AMPK—a protein that maintains energy homeostasis—is abnor-
mally active in the brains of mice with HD, but whether the kinase 
protects neurons from the metabolic imbalances associated with 
HD or whether AMPK contributes to neuronal death is unknown.
Ju et al. determined that the 1 isoform of AMPK was specifi  -
cally activated and translocated into the nuclei of neurons in a mouse 
model of HD, whereas AMPK-2 was unaffected. An inhibitor of 
Ca2+/calmodulin-dependent protein kinase II reduced AMPK activ-
ity, suggesting that AMPK-1 is activated by this kinase, prob-
ably because Ca2+ signaling is disrupted in HD neurons. Further 
stimulation of AMPK by injection of the AMPK-activating drug 
AICAR increased neuronal death and decreased the lifespan of HD 
mice. AICAR also promoted the death of neuronal cell lines, an 
effect reversed by an AMPK inhibitor. Active, nuclear AMPK-1 
promoted neuronal apoptosis by reducing expression of the sur-
vival factor Bcl2. Bcl2 levels and cell survival were restored by 
CGS21680, a drug that alleviates the symptoms of HD mice.
AMPK was also hyperactivated in the brains of human HD 
patients, suggesting that the kinase could be a therapeutic target. 
Senior author Yijuang Chern now wants to investigate how AMPK-
1 and -2 isoforms are differentially regulated in neuronal tissue.
Ju, T.-C., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201105010.
HJURP puts the centromere in place
T
he histone chaperone HJURP 
directs the formation of func-
tional centromeres by assem-
bling the histone variant CENP-A into 
chromatin, Barnhart et al. reveal.
CENP-A is a specialized version of 
histone H3 that marks the position of cen-
tromeres. A protein called HJURP helps 
deliver CENP-A to centromeric chroma-
tin, but whether HJURP simply protects 
CENP-A until the histone is incorporated 
or whether the protein actively assembles 
CENP-A into nucleosomes is unclear.
Barnhart et al. targeted HJURP to noncentromeric chroma-
tin by tagging it with the Lac repressor protein LacI and express-
ing this fusion protein in cells carrying an array of LacI-binding 
DNA sequences on one of their chromosomes. LacI-HJURP 
bound to this array and stably incorporated CENP-A into the 
underlying chromatin. Moreover, additional centromeric and 
kinetochore proteins were also recruited to the array, allowing 
it to stably attach to spindle microtubules during mitosis.
A short N-terminal fragment of HJURP fused to LacI was suf-
fi  cient to assemble these ectopic kinetochores. This same fragment—
which contains the Scm3 domain conserved in yeast homologues of 
HJURP—could also assemble CENP-A into DNA-bound nucleo-
somes in vitro. Centromeric nucleosomes have been proposed to dif-
fer in size and structure from regular nucleosomes, but the CENP-A 
nucleosomes formed by HJURP in vitro were octameric and con-
tained negatively supercoiled DNA, just like canonical nucleosomes.
Barnhart et al. found that HJURP normally requires the centro-
meric protein complex Mis18 to localize to centromeres. Senior author 
Daniel Foltz now wants to investigate how the Mis18 complex associ-
ates with centromeres and how it recruits HJURP and CENP-A.
Barnhart, M.C., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201012017.
The kinetochore protein 
NDC80 (green) is recruited 
to an ectopic location by 
the N terminus of HJURP 
fused to LacI (red).
Sphingomyelinase helps bones get their minerals
K
havandgar et al. 
demonstrate that 
bone-forming osteo-
blasts require the enzyme 
neutral sphingomyelinase 2 
(nSMase2) to mineralize the 
extracellular matrix during 
skeletal development.
nSMase2 cleaves sphingomyelin to generate ceramide and 
other bioactive lipids. Mice lacking nSMase2 have severe skel-
etal abnormalities such as shortened and bent limb bones. The 
precise nature of these skeletal defects has remained unclear, 
however, as has the site of nSMase2’s action. Some studies have 
suggested that nSMase2 acts in the brain to regulate endocrine 
signals controlling bone development.
Khavandgar et al. analyzed mice lacking nSMase2 activity 
due to a chemically induced mutation called fragilitas ossium (fro) 
and found that although their osteoblasts differentiated and secreted 
collagen matrix as normal, they failed to mineralize this matrix 
with calcium and inorganic phosphate. Mutant osteoblasts also 
failed to mineralize in culture. In addition, the long bones of fro/fro 
embryos contained increased numbers of hypertrophic chondro-
cyte-like cells that normally die during long bone growth. Restoring 
wild-type nSMase2 expression to the osteoblasts of fro/fro mice res-
cued the bone mineralization and skeletal defects of these animals. 
Osteoblast-specifi  c nSMase2 expression failed to boost hypertrophic 
chondrocyte apoptosis, however, indicating that nSMase2 has tissue-
specifi  c functions during skeletal development.
The results may explain why some osteogenesis imper-
fecta patients have bone mineralization defects despite having 
intact collagen genes and normal levels of mineral ions in their 
serum. Senior author Monzur Murshed now wants to investi-
gate how nSMase2 promotes mineralization. The enzyme may 
regulate the release of specialized matrix vesicles from osteo-
blasts that initiate the mineralization process.
Khavandgar, Z., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201102051.
Injection of an AMPK activator 
(right) increased the number of 
apoptotic neurons (red) in the 
striatum of mice with HD.
Compared to wild type (left), the 
absence of black staining indicates 
the reduced mineralization of 
bones lacking nSMase2 (right).